Introduction
Colorectal carcinoma is the second most common cause of cancer death in the Western world, and causes around 55 000 deaths per year in the USA. 1 Most patients will develop liver metastases at some stage of their disease and nearly all will die. The optimum treatment for patients with isolated metastases is surgical resection but this is only applicable in a minority of affected patients. [2] [3] [4] The treatment of metastatic colorectal cancer has centered on 5-fluorouracil (5FU), with improved response rates when used in combination with biochemical modulators such as folinic acid and an improvement in long-term survival. 5, 6 Liver metastases derive most of their blood supply from the hepatic artery, in contrast to normal liver hepatocytes, which have a dual supply via the hepatic portal vein, as well as the hepatic artery. 7, 8 Regional delivery of 5FU or 5-fluoro-2-deoxyuridine (FUDR) via the hepatic artery permits higher localized drug concentrations to be delivered to the liver metastases, thereby increasing response rates and reducing systemic toxicity. [9] [10] [11] [12] [13] [14] [15] [16] FUDR is the most widely used drug for hepatic intra-arterial chemotherapy with response rates of 50-80%, with 90% of the drug extracted by the liver, but hepatic toxicity may occur in over 40% of patients. [9] [10] [11] There is less hepatic toxicity with 5FU but the first pass effect is much lower than that for FUDR, allowing for a spill over into the systemic circulation. Both 5FU and FUDR increase response rates substantially when delivered via the hepatic artery compared with systemic administration, but the extent of any long-term survival benefit is debatable. 12, 13 Response rates using regional delivery of 5FU with folinic acid and/or systemic therapy have been encouraging but toxicity is still a problem at high doses. [14] [15] [16] Gene directed enzyme prodrug therapy (GDEPT) potentially could deliver much higher doses of toxic metabolite more effectively to tumours than conventional cytotoxic drugs. Successful GDEPT requires selective tumour uptake of the suicide gene, efficient conversion of the prodrug to a toxic metabolite and a prominent bystander effect. The Herpes simplex virus thymidine kinase (HSV-TK)/ganciclovir (GCV) and the Escherichia coli cytosine deaminase gene (CD)/5-fluorocytosine (5FC) are two enzyme/prodrug combinations which have been used to treat experimental colorectal liver metastases by direct local injection. 17, 18 Both these gene therapy strategies appear to produce effective antitumour responses in vitro and in vivo, but the CD/5FC system has two potential advantages over HSV-TK/GCV. [19] [20] [21] [22] [23] [24] [25] [26] [27] In vitro, a greater bystander effect has been observed with CD/5FC compared with HSV-TK/GCV. 24, 28 Unlike phosphorylated GCV (the toxic metabolite of GCV), the bystander effect of 5FC is maintained in the absence of gap junc-tional intercellular communication (which tends to be lost in transformed cells) since 5FU (the major catabolite of 5FC) can diffuse across cell membranes. 24, 28 In vivo, HSV-TK/GCV treatment of liver tumours has been associated with significant treatment-related mortality due to hepatotoxicity although there is uncertainty as to the mechanism. 27, 29, 30 Previously it has been demonstrated that targeting of colorectal cancer cells can be effectively undertaken using the tumour-specific embryonic antigen (CEA) linked to CD. 25 The growth of tumours generated in SCID mice by subcutaneous injection of NCI H508 cells transduced with CEA/CD-145 were suppressed following intraperitoneal treatment with the 5FC prodrug. 25 We hypothesised that the blood supply of liver metastases also could be exploited for GDEPT. In a similar way to that demonstrated by the promising experience of regional chemotherapy, regional delivery of GDEPT might achieve better selectivity in tumour targeting, resulting in greater transfection efficiency.
Progress has been hampered, however, by the lack of clinically relevant in vivo models. We used a rat model of colorectal cancer liver metastasis, in which the metastases were established and visible as miliary surface deposits before any therapy was started. Because it was a syngeneic model, the confounding factors of cross-species immunity and immuno-deficiency on the true therapeutic effects were avoided. In vitro treatment with CEA-CD-113 retrovirus and 5FC efficiently killed rat K12 colonic adenocarcinoma cells with a significant bystander effect. Following a single regional arterial injection of the CEA-CD-113 retrovirus via the hepatic artery and subsequent intraperitoneal administration of 5FC, there was substantial growth suppression of liver metastases associated with the elimination of previously established multiple surface metastases. For the first time, we have demonstrated the effectiveness of GDEPT using a tumourspecific promoter combined with regional vector delivery for the treatment of colorectal liver metastases. These results prompt the development of this approach for clinical trials.
Results
Integration and expression of cytosine deaminase in K12 cells K12 cells infected with the retroviral construct were selected by their resistance to G418. The expression of CD in those cells infected with the retroviral CEA-CD-113 construct was demonstrated by Western blot analysis using a polyclonal specific CD antibody (Figure 1 ). Further- H-uracil (99%), unlike wild-type cell lysate, which showed negligible conversion of cytosine to uracil (Table 1) .
In vitro sensitivity of K12 CEA-CD cells to 5-fluorocytosine Parental K12 cells and K12 CEA-CD cells were treated with 5FC over the range 0-2 mg/ml. The 50% inhibitory concentration (IC 50 ) for parental cells was 1 mg/ml compared to 0.055 mg/ml K12 CEA-CD cells, a 36-fold difference (Figure 2a) . A relative significant in vitro bystander effect was demonstrated by mixing CEA-CD-113 infected K12 cells in various percentages with non-infected cells and grown in the presence of 5FC (0.2 mg/ml). For example, 5FC administration resulted in 92% cell death with only 40% of the cells in the mixture from the K12 CEA-CD cell pool, compared to the death rate inflicted on cells derived entirely from the K12 CEA-CD cell pool (Figure 2b) .
Expression of the retroviral vector in vivo
CD protein, however, was detected in liver tissue lysates by Western blot analysis, 24 h and 48 h after retroviral treatment in the time-course group of animals ( Figure 3a) . CD protein was not detected in normalappearing liver from any of the groups, nor from tumour tissue obtained at death.
Therapeutic effect of direct hepatic arterial injection of CEA-CD-113 retrovirus with systemic administration of 5-fluorocytosine in vivo
The mean tumour volumes in animals treated by hepatic artery injection CEA-CD-113 then 5FC i.p. were eight- Cytosine deaminase activity was assessed using TLC. Lysates were prepared from K12 cells infected in different experiments (signified by numbers 1-3), and the parental cell line. These lysates were incubated with 3 H-cytosine at 37°C for 18 h. 3 H-cytosine and 3 H-uracil were then separated using thin layer chromatography, and quantified by liquid scintillation. The purified yeast recombinant CD protein (5 l, 0.25 U) was used as a positive control.
Figure 2 In vitro cytotoxicity assays. (a) MTT cytotoxicity assay. K12 parental and K12 CEA-CD-113 infected cells were incubated in the pres
- ence of 5FC (0, 2 × 10 −4 , 2 × 10 −3 , 2 × 10 −2 , 2 × 10 −1 , 1
and 2 mg/ml). The plot shows the percentage cell viability versus log 5-fluorocytosine concentration (mg/ml). The IC 50 for K12 parental cell line was 2 mg/ml and the IC 50 for K12 CEA-CD cells was 0.055 mg/ml. The results represent the mean of eight samples ± s.e.m. (bars). (b) In vitro neighbour cell k ± s.e.m. effect of K12 CEA-CD-113 infected cells on non-infected K12 parental cells. Co-cultures were grown in the presence of 5FC (0.2 mg/ml). The plot shows the percentage relative cell viability versus % K12 CEA-CD cells. The results represent the mean of eight samples ± s.e.m. (bars).
fold less compared with all other treatment groups ( Figure 3b ; P Ͻ 0.002). The mean tumour volumes were very similar in the three control groups. The livers from animals at the end of active treatment either had only a few visible surface metastases ( Figure 4b ) and sometimes none (Figure 4c ), compared with the scores of small surface tumours before treatment. The livers from animals at the end of treatment in the control groups had scores of surface liver tumours demonstrating confluence ( Figure 4d , e, f).
Histology
The histological appearance of liver sections unaffected by metastases from both the treatment and control groups was entirely normal. There was no evidence of any hepatotoxicity including livers from those animals that had had treatment with CEA-CD-113 and 5FC (data not shown).
Microscopic examination of liver sections from all treatment groups showed liver metastases as discrete tumour nodules composed of poorly differentiated adenocarcinoma cells. The metastatic tumours were located mostly beneath Glisson's capsule. Increased numbers of lymphocytes were grouped around the periphery of each tumour nodule from where the lymphocytes appeared to be infiltrating into the tumour. Typically, tumours contained one or more zones of necrosis. Apart from their number and size, the histological appearances of the tumours were similar in all the groups. There was no histological evidence of systemic toxicity in the heart, spleen, kidney or lungs of animals from any of the groups.
Discussion
The present study has demonstrated that infection of the retrovirus CEA-CD-113 construct into the rat K12 adenocarcinoma cell line resulted in functional intracellular enzyme activity and exposure of these cells to 5FC resulted in significant growth inhibition. Expression of CD was demonstrated by Western blot analysis and shown to be functional by the cytosine deaminase activity and cytotoxicity assays. Previously, this and similar constructs have been transfected into a variety of human cell lines with widely differing levels of latent CEA production. 25 Cell lines that had high levels of CEA expression as demonstrated by a CEA-luciferase reporter, expressed more CD protein and were more susceptible to the 5FC prodrug. Of particular importance to the development of this GDEPT strategy for the treatment of colorectal liver etastases, was the observation that liverderived cell lines had low levels of CEA expression and low levels of CD transcription following infection with the CEA-CD constructs. 25 Infected K12 cells were 36-fold more sensitive to 5FC compared with the parental rat cell line, which compares well with the 60-fold greater sensitivity of the human colorectal cell line WiDr when infected with CEA-CD-113 and exposed to 5FC relative to the parental cell line. 25 Even greater expression of CD by up to 1000-fold has been obtained in WiDr cells by using the cytomegalovirus promoter. 21 The use of the CEA tumour-specific promoter provides selective expression, consequently minimising local and systemic toxicity. 31 Previously, a significant in vitro bystander effect has been shown for CD/5FC when using powerful constitutive promoters, but in this study we were able to demonstrate a similar phenomenon using a tumour-selective promoter. 22, 28 The extent of the in vitro bystander effect is dependent upon a variety of factors, including the strength of expression of the suicide gene, the mode of action and diffusibilty of the catabolite, the density of the cell population and the cell type. 22, 28, [32] [33] [34] Cytosine deaminase, a bacterial and yeast enzyme, deaminates cytosine to uracil and produces 5FU from 5FC. 20 The metabolites of 5FU kill the cell by disrupting RNA processing (5-fluorouracil triphosphate is incorporated into RNA) and DNA synthesis (fluoro-2-deoxyuridine 5′monophosphate inhibits thymidylate synthase). HSV-TK produces cell death by converting GCV to GCV triphosphate, which acts as a chain terminator in DNA synthesis. 35 In vitro bystander effect mechanisms include diffusion of metabolites across cell membranes, intercellular transfer via gap junctions and diffusion of apoptotic vesicles. 24, 28, 36, 37 Although the phosphorylated metabolites of 5FU, like GCV triphosphate are unable to traverse intercellular gap junctions efficiently, 5FU itself diffuses readily across cell membranes. 24, 28 In vivo, there may be an additional benefit from immunological bystander effects. 23 Previous studies using an adenoviral vector containing CD driven by the CMV promoter administered either by direct hepatic parenchymal or tail vein injection, followed by systemic administration of 5FC, have shown significant reductions in tumour growth in livers of nude mice. 18, 38 The present study chose to improve targeting to colorectal liver metastases by using the CEA promoter to drive CD expression and to use regional hepatic intraarterial delivery of the gene vector (in a syngeneic rat model), mimicking established clinical protocols. [9] [10] [11] [14] [15] [16] Following delivery of the CEA-CD-113 retroviral vector by regional arterial injection, expression of CD in liver metastases was demonstrated by Western blot analysis of tumour tissue lysates after 24 h and 48 h but not at 7 days. Significant reduction in tumour growth was observed in animals that received the CEA-CD-113 retrovirus and i.p. 5FC compared with all of the control groups. Effective tumour killing despite relatively low infection levels emphasises the value of immune and non-immune bystander mechanisms. 22, 23, 28 In clinical studies prolonged expression of CEA-CD-113 could be achieved by repeated injections of the retrovirus and further treatment with 5FC using an implantable arterial catheter and port. Alternatively, greater titres could be obtained using an adenoviral vector containing a CEA-CD construct, which has been shown to be effective against CEA-producing gastric cancer cell lines. 31 This approach, however, may restrict repeated vector delivery due to the immune response mounted against recombinant adenoviruses. 39 In contrast to metastatic tumour cells, hepatocytes are relatively quiescent, which means that the use of retroviral vectors will add an additional targeting factor, in that integration and expression is limited to dividing cells. 40 Administration of the 5FC prodrug by intra-peritoneal injection will produce very high initial levels in the hepatic portal circulation. Thus, even if only a relatively small fraction of the blood supply to the developing experimental metastases was derived from the portal circulation, each prodrug injection would result in a large bolus being delivered to the tumor. 7, 8 In clinical studies, the prodrug would be given repeatedly via a catheter port system connected to the hepatic artery to maximise prodrug concentration levels.
In the present set of studies there was no evidence of hepatic or systemic toxicity. Significant hepatotoxicity and a high (47%) mortality rate was reported after portal vein administration of a recombinant adenovirus carrying the HSV-TK gene in ganciclovir-treated rats with carcinogen-induced hepatocellular carcinoma. 29 Severe liver dysfunction and mortality was also found following the administration of ganciclovir in tumour-bearing and non-tumour-bearing in a rat model of colorectal liver metastases given adenovirus vectors carrying HSV-TK. 27 Intravenous injection of a similar adenoviral construct into immunodeficient (SCID and Balb/c) mice resulted in preferential infection of HSV-TK in liver tissue. 30 Administration of HSV-TK into subcutaneous tumours followed by systemic injection of ganciclovir was relatively effec-tive and safe. The administration of ganciclovir by other routes, however, including the tail vein, the hepatic portal vein, or by direct injection into tumours established by parenchymal liver injection of cell lines, has resulted in severe hepatotoxicity and a very high mortality. 30 These findings are surprising in that the principle mode of action of ganciclovir triphosphate is to inhibit DNA polymerase-␣ and therefore only kill dividing cells and suggest an additional mode of action. 30, 40 The experiments reported here support the concept of regional arterial delivery of CEA-CD and systemic 5FC as an effective treatment for colorectal liver metastases. The efficiency of prodrug conversion might be even further enhanced by the use of cytosine deaminase derived from yeast rather than bacteria. 41 In clinical practice, the use of implantable ports would allow repeat administration of the vector and also repeat and/or continuous regional delivery of 5FC, enabling even higher selective concentrations to be achieved.
Materials and methods

Cell culture
The rat colonic carcinoma cell line DHD/K12/TRb was obtained from the European collection of animal cell culture (ECACC, Salisbury, UK: 90062901). This K12 rat cell line was grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) heat-inactivated fetal calf serum (Gibco-BRL, Paisley, UK), 2 mm l-glutamine, 50 U/ml penicillin and 50 g/ml streptomycin, and incubated at 37°C in 5% CO 2 in air.
Retroviral vectors
The retroviral vector CEA-CD-113, contained an (E. coli) cytosine deaminase gene driven by human carcinoembryonic antigen (CEA) promoter, constructed as previously described. 19, 25 The vector contained the gene encoding for neomycin resistance (NeoR), which enabled positive selection for transfectants by conferring resistance to the neomycin analogue G418 (Gibco-BRL, UK). The suffix CEA-CD indicates that the cell line was infected with the retrovirus containing the CEA-CD-113 construct. The retroviral titre was determined by infecting K12 cells (5 × 10 4 cells/ml) plated into each well of a flat-bottomed 24-well plate, with serial dilutions of the concentrated retrovirus in the presence of polybrene (16 g/ml) (Sigma, Poole, UK). After incubation for 1 h, DMEM medium was added to each well and left for a further 24 h. The medium was then replaced with DMEM plus G418 (800 g/ml), except in control wells where the cells received medium only. Every 48 h the medium was replaced plus or minus G418. On day 10, medium was removed from the plate and 0.5 ml of crystal violet (2.5 mg/ml dissolved in 80% methanol) was added to each well. After 30 min the stain was washed out gently in tap water, rinsed and air-dried. Transfectants were counted and an average of three dilutions was taken as the titre, expressed as colony forming units per ml (c.f.u./ml).
Retroviral infection of cells K12 cells (1 × 10
5 cells/ml) were plated into 25-mm tissue culture flasks. After 24 h incubation, cell culture medium was replaced with retrovirus (1 × 10 6 c.f.u./ml) in the presence of polybrene (25 g/ml final concentration) and incubated for 3 h. DMEM (4 ml) was then added and incubated for a further 24 h. The medium was then replaced with DMEM plus G418 (800 g/ml), and transfectants were selected. These cells were then used in the cytotoxicity and bystander assays.
Identification of the cytosine deaminase protein in infected cells
Exponential phase K12 and K12 CEA-CD cells were harvested and washed in phosphate-buffered saline (PBS) (0.02% (w/v) KCl, 0.02% (w/v) KH 2 PO 4 , 0.8% (w/v) NaCl, 0.15% (w/v) NaH 2 PO 4 ) (Gibco-BRL). The cell were resuspended in 200 l of lysis buffer (50 mm Tris-HCl pH 7.5, 1 mm EGTA (ethylene glycol-bis(␤-aminoethyl ether) N,N,N′,N′-tetraacetic acid), 5 mm EDTA (ethylenediaminetetraacetic acid), 1% Triton-X 100, 1 mm MgCl 2 , proteinase inhibitors pepstatin (10 g/ml), leupeptin (1 g/ml), PMSF (phenylmethylsulfonyl fluoride) (80 g/ml) and aprotonin (10 g/ml) and sonicated for 10 s. The cell suspension was then spun at 6700 g for 20 min at 4°C, and the clear cell lysate removed. Total protein concentrations were determined using the Bradford protein assay (Bio-Rad, Hemel Hempstead, UK). 42 Fifty g of total protein were resolved on 15% SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and transferred to a 0.2 m nitrocellulose filter (Bio-Rad). CD was identified using specific rabbit antiserum (1:10 000) (Glaxo Wellcome, Stevenage, UK) with anti-rabbit IgG whole molecule peroxidase conjugate (1:5000) (Sigma) as the secondary antibody and detected by peroxidase-induced chemiluminescence (ECL kit; Amersham Life Sciences, Little Chalfont, UK).
In vitro evaluation of cytosine deaminase activity
Cytosine deaminase activity was determined by quantifying the conversion of ) were washed in PBS, centrifuged at 350 g for 5 min at room temperature. The supernatant was removed and the pellet stored at −70°C. The pellet was quickly thawed at 37°C and resuspended in 15 l of 100 mm Tris HCl pH 7.8, 1 mm EDTA, 0.2% NP-40 (nonylphenoxy polyethoxy ethanol). This was incubated on ice for 15 min and vortexed at regular intervals. A soluble extract was prepared by centrifugation at 6700 g for 20 min at 4°C, to remove cell debris. Total protein concentrations were determined using the Bradford protein assay (Bio-Rad). 42 Five microliters of cell lysate containing 100 g of total protein was added to 5 l of 3 H-cytosine (0.45 Ci per 5 l) (Sigma) and incubated at 37°C for 18 h. These samples and 10 l of a marker solution containing unlabelled 5 mm cytosine (Sigma) and 10 l of unlabelled 5 mm uracil (Sigma) dissolved in Tris HCl pH 7.8, 1 mm EDTA, were run on fluorescent thin-layer chromatography plates (Sigma), and developed in 86% 1-butanol (BDH, Poole, UK). After drying, bands corresponding to cytosine and uracil were cut out under UV illumination and assayed by liquid scintillation. Percentage conversion of cytosine to uracil was calculated by dividing the DPM (disintegrations per minute) of uracil by the DPM of uracil and cytosine. The positive control was yeast cytosine deaminase protein 5 l (50 U/ml) (Biogenesis, Poole, UK) and the negative controls were buffer alone or non-infected K12 cell lysate.
Gene Therapy
In vitro cytotoxicity assay A total of 2 × 10 3 K12 and K12 CEA-CD cells suspended in 200 l of DMEM were plated per well into a flatbottomed 96-well Costar tissue culture dish. After 24 h this was replaced with DMEM plus 5FC (0-2 mg/ml) (Sigma), whilst control wells received DMEM only. After 48 h medium was changed plus or minus 5FC and left for a further 24 h. Medium was then removed and viable cells determined using the dimethylthiazol diphenyl tetrazolium (MTT) assay (Sigma). MTT (0.5 mg/ml) in cell medium was added to each well and incubated at 37°C for 5 h. The supernatant was aspirated and formazan crystals solubilized with 200 l of DMSO (dimethyl sulphoxide). Absorbance at 570 nm was read using an ELISA plate reader (SLT Labinstruments, Salzberg, Austria). Results were expressed as the percentage of growth of untreated cells. Each experiment was undertaken using eight wells per variable and performed at least twice.
In vitro bystander assay K12 and K12 CEA-CD cells were mixed in various percentages and co-cultured in a 96-well plate (a total of 2 × 10 3 cells per well). After 48 h medium was removed and replaced with medium plus 5FC (0.2 mg/ml), whilst controls received medium only. After a further 48 h medium was replaced again and left for a further 24 h. Viable cells were determined using the MTT assay as described above. Results were expressed as the percentage growth of untreated cells. Each experiment was undertaken using eight wells per variable and performed at least twice.
Evaluation of retroviral gene transfer in vivo
The syngeneic model for colorectal liver metastases was established in BDIX rats using the rat K12 colon adenocarcinoma cell line. Male rats aged between 8 and 12 weeks old and weighing more than 250 g were used (mean weight ± s.e.m., 287.1 ± 4.0 g). At the first laparotomy K12 cells (1 × 10 7 ) in 0.7 ml of phosphate-buffered saline (PBS) were injected into the hepatic portal vein. Hepatic metastases were then left to develop for 10 days, at which time multiple small tumour nodules were visible on the liver surface (Figure 4a) .
Livers from experimental animals with metastases were killed at 24 h and 48 h following administration of retrovirus then assayed for CD expression in specific time-course experiments. As in the therapeutic studies, 1 × 10 7 c.f.u. of CEA-CD-113 retrovirus in PBS was injected into the hepatic artery. Livers were also assayed from animals with metastases that had been involved in therapeutic experiments obtained at death (9 days after administration of retrovirus).
Liver tissue lysates were prepared from snap-frozen tissue. The tissue was first crushed using a pestle and mortar, and resuspended in 400 l of 100 mm Tris-HCl pH 7.8, 1 mm EDTA, 0.2% NP-40. The tissue suspension was homogenized and spun at 6700 g for 10 min at 4°C. The protein concentration of the cleared tissue lysate was then determined using the Bradford assay. 42 One hundred g of total protein was separated on a 15% SDS-PAGE gel and transferred to a nitrocellulose filter and detected as before.
In vivo syngeneic model
Multiple liver metastases were generated by injecting 1 × 10 7 K12 cells in 0.7 ml of PBS into the hepatic portal vein. These liver metastases were clearly visible at the second laparotomy 10 days later. One team and one principal technical operator performed all the procedures. At the second laparotomy the celiac, hepatic and gastroduodenal arteries were identified. The solution containing concentrated retroviral vectors (1 × 10 7 c.f.u.) or PBS was injected via a cannula (2FG, SIMS Portex, Hythe, UK) inserted into the gastroduodenal artery. After a further 48 h, i.p. injections of 5FC (dissolved in PBS) or PBS were administered twice daily for 7 days, before the animals were killed. The daily dose of 5FC administered was 500 mg/kg. The animals were randomized into four groups, each containing six animals completing the whole experiment. There was one therapeutic (1) and three control groups (2, 3 and 4) as follows: (1) hepatic artery CEA-CD-113 then 5FC i.p.; (2) hepatic artery CEA-CD-113 then PBS i.p.; (3) hepatic artery PBS then 5FC i.p.; and (4) hepatic artery PBS then PBS i.p.
At death all the major organs, including the liver were removed for histology or snap-frozen for further analysis. Tumour volumes were calculated by measuring the length, width and depth of the tumours by two independent observers blinded to each other's results and then averaged. Procedures in animal experiments were performed with approved protocols and in accordance for the proper care and use of laboratory animals (Home Office approved licence 40/1750).
Histology
Organs including the liver, lungs, kidneys, spleen and heart, from all groups of animals were fixed in 4% formalin for 20 h. The tissues were then embedded in paraffin and 5-m sections were cut and then stained with haematoxylin and eosin. A senior pathologist experienced in human and experimental histology, who was blinded to their identity, examined the slides.
Statistical analysis
Values of the cytotoxicity and the bystander assay were expressed as the mean ± s.e.m. of eight wells. Each experiment was repeated at least twice; the graphs depict a single experiment of eight wells per variable. Tumour volumes were calculated and compared between the different groups using the Kruskall-Wallis and two-tailed Mann-Whitney U tests. Significance was set at P Ͻ 0.05.
